Wesam Gouda, MBBCh, MSc; Abdelhafeez Moshrif, MBBCh, MSc, MD; Fatma H. El Nouby, MBBCh, MSc, MD; & Amal Fehr, MBBCh, MSc, MD | Issue: September 2019 |
Seeing vessels clearly can help with discovery and timely treatment
No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.
Advances in genetics and potential therapies shed new light on the disease
Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…